ADULT T-CELL LEUKEMIA/LYMPHOMA
Clinical trials for ADULT T-CELL LEUKEMIA/LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ADULT T-CELL LEUKEMIA/LYMPHOMA trials appear
Sign up with your email to follow new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo tackles rare leukemia: hope for ATLL patients
Disease control TerminatedThis early-phase trial tests whether adding lenalidomide to standard chemotherapy (EPOCH) is safe and effective for adult T-cell leukemia-lymphoma (ATLL), a rare blood cancer linked to HTLV-1 infection. About 30 adults with certain subtypes of ATLL will receive the combination to…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
New combo therapy shows promise against hard-to-treat t-cell lymphoma
Disease control OngoingThis study tested a new treatment for people with a rare blood cancer called CD30-positive peripheral T-cell lymphoma. The treatment combines a targeted drug (brentuximab vedotin) with standard chemotherapy. The goal was to see how well the combination works and what side effects…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New hope for Tough-to-Treat lymphoma: experimental drug shows promise
Disease control OngoingThis study tests an experimental drug called valemetostat in people with a rare blood cancer (peripheral T-cell lymphoma) that has returned or not responded to other treatments. About 155 adults will receive the drug to see if it shrinks tumors and to check for side effects. The …
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New drug combo aims to shrink Hard-to-Treat lymphoma
Disease control TerminatedThis early-stage trial tests whether combining two drugs, azacitidine and abatacept, can shrink tumors in adults with T-cell lymphoma that has come back or not responded to prior therapy. About 20 participants will receive the drugs in 28-day cycles for up to 13 cycles. The study…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 05, 2026 12:05 UTC